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Although the nucleotide-binding oligomerization domain- (NOD-) like receptor pyrin domain containing 3 (NLRP3) inflamma-
some has been recently detected in the heart, its role in cardiac ischemia/reperfusion (IR) is still controversial. Here, we investigate
whether a pharmacological modulation of NLRP3 inflammasome exerted protective effects in an ex vivo model of IR injury.
Isolated hearts from male Wistar rats (5-6 months old) underwent ischemia (30min) followed by reperfusion (20 or 60min) with
and without pretreatment with the recently synthetized NLRP3 inflammasome inhibitor INF4E (50𝜇M, 20min before ischemia).
INF4E exerted protection against myocardial IR, shown by a significant reduction in infarct size and lactate dehydrogenase release
and improvement in postischemic left ventricular pressure. The formation of the NLRP3 inflammasome complex was induced
by myocardial IR and attenuated by INF4E in a time-dependent way. Interestingly, the hearts of the INF4E-pretreated animals
displayed amarked improvement of the protective RISK pathway and this effect was associated increase in expression of markers of
mitochondrial oxidative phosphorylation. Our results demonstrate for the first time that INF4E protected against the IR-induced
myocardial injury anddysfunction, by amechanism that involves inhibition of theNLRP3 inflammasome, resulting in the activation
of the prosurvival RISK pathway and improvement in mitochondrial function.
1. Introduction
Ischemic heart disease is one of the main culprits of illness
and death [1, 2]. The main outcome of a transient cardiac
ischemia is the progressive decline of the left ventricle
contractile function, frequently paralleled by impairment
of the mitochondrial energy metabolism [3, 4]. During
the reperfusion phase the sudden mitochondrial oxygen
overload induces oxidative stress and further worsens the
metabolic derangement [4], thus paradoxically exacerbating
myocardial injury and inducing pyroptosis [2, 5]. Pyroptosis
is a caspase-1-dependent process leading to cell lysis, which
has been demonstrated to be strongly regulated by the mul-
tiprotein platform complex nucleotide-binding oligomeriza-
tion domain- (NOD-) like receptor pyrin domain contain-
ing 3 (NLRP3) inflammasome. The NLRP3 inflammasome
comprises (a) NLRP3, (b) an apoptosis-associated speck-like
protein containing a caspase activation recruitment domain
(ASC), and (c) procaspase-1. In response to a wide range
of danger signals, including oxygen-free radicals, K+ efflux,
or mitochondrial stress [6–8], NLRP3 recruits the adaptor
protein ASC which in turn interacts with procaspase-1.
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Inflammasome oligomerization promotes the autocatalytic
activation of procaspase-1 and the processing of prointer-
leukin- (IL-) 1𝛽 [2]. More recently, a new protein has been
identified as member of the NLRP3 inflammasome com-
plex, the Gasdermin D (GSDMD), which is recruited with
kinetics similar to those required for caspase-1 activation.
The proteolytic cleavage of GSDMD by caspase-1 detaches
its N-terminal fragment, which contributes to mediate IL-
1𝛽 secretion and pyroptosis [9]. Since NLRP3 is detectable in
many cardiac cell types, including cardiofibroblasts (themost
important cell type in the heart in terms of number of cells)
and cardiomyocytes (the most important cell type in terms of
cell volumes), it is likely that it may play a pivotal role in acute
myocardial infarction [10, 11]. Indeed, we and others have
shown that NLRP3 is upregulated by ischemia/reperfusion
(IR) injury and its myocardial activation is exacerbated by
metabolic derangements [12, 13]. Interestingly, genetic mod-
ulation of NLRP3 has been reported to reduce myocardial
infarct sizes upon IR [13]. However, a very recent study failed
to find any role of NLRP3 in determining myocardial IR
injury [14] and another investigation supported cardiopro-
tective effects due to NLRP3 inflammasome activation, thus
highlighting that the interpretation of NLRP3 inflammasome
role in myocardial IR injury is far from clear. Nevertheless,
a cross-talk between NLRP3 and mitochondria, the main
player of IR injury, has been described, with NLRP3 being
able to sense the presence of reactive oxygen species (ROS)
produced by normal or dysfunctional mitochondria [15].
Thus, the present study aimed to investigate the effects of a
newly synthesized NLRP3 inflammasome inhibitor, named
INF4E [16], in an ex vivo model of myocardial IR injury.
We deepened our investigation evaluating its ability, in
the rat heart, (i) to interfere with the IR-induced NLRP3
inflammasome activation and pyroptotic cascade and (ii) to
improve the mitochondrial metabolic response to IR insult.
2. Materials and Methods
2.1. INF4E Preparation. INF4E was dissolved at 200mM
concentration in DMSO. Stock solution was then diluted at
a final concentration of 50𝜇M in the perfusion buffer (see
below). The description of the synthesis and the specificity
of the inhibitor is included in the Supplemental Material
(available online at http://dx.doi.org/10.1155/2016/5271251),
according to previous publications [16, 17].
2.2. Animals Protocol and Ex Vivo Ischemia/Reperfusion (IR)
Injury. Male Wistar rats (Harlan Laboratories, Udine, Italy)
5-6 months old, reaching a body weight of 450–550 g, were
cared in compliance with the EuropeanDirective 2010/63/EU
on the protection of animals used for scientific purposes.The
animal protocols followed in this study were approved by the
local “Animal Use and Care Committee.” After one week of
quarantine, with drink and food ad libitum, rats were anes-
thetized and killed. The hearts were rapidly perfused. A con-
stant flow was maintained to obtain a typical coronary perfu-
sion pressure of about 80mmHg by the Langendorff tech-
nique with Krebs-Henseleit bicarbonate buffer containing
(mM) NaCl 118, NaHCO3 25, KCl 4.7, KH2PO4 1.2, MgSO4
1.2, CaCl2 1.25, and Glucose 11. The buffer was gassed with
95% O2 : 5% CO2. The temperature of the perfusion system
was maintained at 37∘C. The hearts underwent 30min stabi-
lization and then were exposed to 30min of global no-flow,
normothermic ischemia followed by a period of 20 or 60min
of reperfusion. Hearts from a subgroup of rats (IR+INF4E)
were pretreatedwith 50𝜇MINF4E in the perfusate for 20min
before ischemia (after the first 10min of stabilization). Hearts
from sham animals were exposed to 60min perfusion only
and served as reference group in Western blot analysis.
The hearts were electrically paced at 280–300 bpm and
kept in a temperature-controlled chamber (37∘C). Pacing
was stopped at the beginning of the ischemia and restarted
after the third min of reperfusion. Left ventricular pressure
(LVP) and coronary perfusion pressure (CPP) were recorded
and monitored with two electromanometers placed within
the left ventricle and along the perfusion line, respectively.
Coronary flow, CPP, and LVP were used as indices of
preparation conditions. Moreover, end diastolic LVP was
recorded as index of contracture development during I/R and
developed ventricular pressure as index of contractile activity
throughout the experiment using PowerLab data acquisition
system and analyzed using Chart software (ADInstruments,
Oxford, UK).
The perfusate flowing out of the heart was collected for
measurement of lactate dehydrogenase (LDH) release 5min
immediately before ischemia and for the entire reperfusion
period. To assess the conditions of experimental preparation
the coronary flow rate was determined by the amount of
perfusate measured in a specific time period. The heart was
then cut in two parts by a coronal section (perpendicular to
the long axis). The apical part (less than 1/3 of ventricular
mass) was used for molecular analysis and, thus, frozen
rapidly in liquid nitrogen and stored at −80∘C. Infarct
size assessment was performed by using the basal part of
ventricle.
2.3. Measurement of the Infarct Size. Infarct mass was eval-
uated at the end of the reperfusion with the nitro-blue-
tetrazolium (NBT) technique by using a gravimetric method
[18]. The basal part of the ventricles was dissected by trans-
verse sections into two/ three slices, which were incubated
for 20min with a solution of NBT (0.1%) in phosphate buffer.
Two independent and blind observers carefully separated and
then weighted both stained and unstained tissues. Total mass
of necrosis was then calculated and expressed as percentage
of ventricular mass. Since the ischemia was global and since
we analyzed only the basal part of the ventricles the necrotic
mass was expressed as a percentage of the analyzed ischemic
tissue.
2.4. LDH Assay. Spectrophotometric analysis at 340 nm was
performed on the collected perfusion effluent to measure
LDH released from the heart.
2.5. Preparation of Tissue Extracts. Total proteins extracts
were obtained from 10% (w/v) apex homogenates in RIPA
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buffer (0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
SDS, 10mmol/l EDTA, and protease inhibitors) as previously
described [19]. Protein concentrations were measured by
Bradford assay (BioRad, Hercules, CA, USA) and samples
were then stored at −80∘C for subsequent analysis.
2.6. Determination of IL-1𝛽 in Hearts Homogenates. Com-
mercially available ELISA kit (R&D Systems, Abingdon,
UK) was used to measure concentrations of IL-1𝛽 in tissue
homogenates, according to the manufacturer’s instructions.
2.7. Western Blot Analysis. Total proteins extracts were sep-
arated by SDS-PAGE and blotted to nitrocellulose mem-
brane (GE-Healthcare Europe, Milano, Italy). Membranes
were incubated with rabbit anti-NLRP3 (Abcam, Cam-
bridge, UK), rabbit anti-caspase-1 (Santa Cruz Biotech-
nology, Dallas, TX, USA), mouse anti-GSDMDC1 (Santa
Cruz Biotechnology), rabbit anti-IL-1𝛽 (Santa Cruz Biotech-
nology), rabbit anti-caspase-1 (Santa Cruz Biotechnology,
Dallas, TX, USA), mouse anti-Tyr204 ERK1/2 (Cell Sig-
naling Technology), rabbit anti-total ERK1/2 (Cell Signal-
ing Technology), mouse anti-Ser473 Akt (Cell Signaling
Technology), rabbit anti-total Akt (Cell Signaling Technol-
ogy), rabbit anti-Ser9 GSK-3𝛽 (Abcam, Cambridge, UK),
anti-total GSK-3𝛽 (Cell Signaling Technology), rabbit anti-
mitochondrial transcription factor A (mtTFA) (Novus Bio-
logicals, Cambridge, UK), mouse anti-nuclear respiratory
factor-1 (NRF-1) (Santa Cruz Biotechnology), and mouse
anti-sarcomeric mitochondrial creatine kinase (sMtCK)
(Santa Cruz Biotechnology) and then probed with proper
HRP-conjugated secondary antibodies (BioRad). Clarity
Western ECL substrate (BioRad) was used for protein detec-
tion and quantification was performed by densitometric
analysis (Quantity-One, Bio-Rad software). Data were nor-
malized according to the related antitubulin densitometric
values.
2.8. Real-Time PCR. Total RNA was extracted from heart
samples using the AllPrep DNA/RNA/protein kit (Qiagen,
Hilden, Germany), according to the manufacture instruc-
tions.The total RNA concentration (𝜇g/mL) was determined
by the fluorometer Qubit and the Quant-iT RNA Assay
Kit (Invitrogen, Milano, Italy). A total of 500 ng of RNA was
reverse-transcribed using QuantiTect Reverse Transcription
Kit (Qiagen). The synthesized cDNA was used for real-
time polymerase chain reaction (RT-PCR). The cDNA was
amplified by real-time PCR using SsoFast EvaGreen (Bio-
Rad,) and primers specific for cytokine IL-1𝛽 (Mm Il1b 2 SG,
cat. number QT01048355, Qiagen). The PCR reaction was
performed at 95∘C for 30 s followed by 40 cycles of 95∘C
for 5 s, 55∘C for 10 s. All samples were run in duplicate.
At least two nontemplate controls were included in all
PCR. The transcript of the reference gene ribosomal RNA
18S (Mm Rn18s 3 SG, cat. number QT02448075, Qiagen)
was used to normalize mRNA data, and the quantification
data analyses were performed by using the Bio-Rad CFX
Manager Software, version 1.6 (Bio-Rad) according to the
manufacturer’s instructions.
2.9. Materials. Compounds here used were obtained from
the Sigma-Aldrich Company Ltd., unless otherwise stated.
2.10. Statistical Analysis. Data described in the text and
figures are presented as means ± standard error of the mean
(s.e.m.) of 𝑛 observations, where 𝑛 represents the number
of animals studied. Statistical analysis was performed using
ANOVA test followed by Bonferroni's posttest. A 𝑃 value of
less than 0.05 was considered to be statistically significant.
3. Results
3.1. INF4E Pretreatment Limits Infarct Size and Improves
Contractility Recovery. Rat hearts exposed to a 30min global
ischemia and 60min reperfusion developed a 60 ± 3%
infarct size in the basal portion of ventricle evaluated by
NBT staining. When hearts were pretreated (20min prior
to ischemia) with INF4E in the perfusate, the infarct size
was significantly reduced compared to untreated hearts (IR)
(Figure 1(a)). Importantly, LDH release in the perfusate was
almost halved by drug treatment (Figure 1(b)). In addition,
the INF4E pretreated hearts showed a twofold increase in
contractile recovery after IR, as assessed by left ventricular
pressure monitoring (Figure 1(c)).
Of note, IR caused an impairment of the mechanical
performance, as evidenced by the dramatic reduction of
developed LVP (DLVP) immediately after ischemia and the
incomplete recovery during reperfusion. In fact, developed
LVP fell from about 80mmHg in the preischemic condition
to about 25mmHg after 10min of reperfusion and then
recovered to only 50mmHg at 60min reperfusion, thus
reaching only less than 65% of the preischemic value (Figures
1(c) and 1(d)). The pretreatment with the NLRP3 inhibitor
did not modify the recovery of DLVP at early reperfusion
time (10 and 20min), whereas an improvement starts to be
detectable after 40min, reaching values up to 85mmHg at
60min, corresponding to over 100% of the preischemic value
at the end of reperfusion.The end diastolic LVP (EDLVP)was
about 5mmHg during stabilization; then, the 30min global
ischemia and the subsequent reperfusion caused a sustained
increase of this parameter in both the IR and IR+INF4E
groups (Figure 1(e)). Actually, an increase of EDLVP was
appreciated immediately after the end of ischemia and con-
tinued during the first 20min of reperfusion. Then EDLVP
further increased in the IR group reaching values over
30mmHg, while in the group pretreated with the NLRP3
inhibitor it decreased progressively to about 20mmHg after 1
hour of reperfusion.The increase in EDLVP was significantly
(𝑃 < 0.05) attenuated by the NLRP3 inhibitor only at 60min
reperfusion.
3.2. INF4E Pretreatment Prevents NLRP3 Inflammasome Acti-
vation and Downstream Signaling. To confirm the ability
of INF4E to interfere with NLRP3 inflammasome complex
formation and activation in our experimental model, the
expression level and the activation of the downstream sig-
naling of NLRP3 inflammasome were assessed by Western
blotting analysis in protein extracts obtained from the apical
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Figure 1: Infarct area, LDH release, and contractility recovery in hearts from rats exposed to 30min of ischemia plus 60min of reperfusion,
pretreated or not with 50𝜇M INF4E in the perfusate 20min before ischemia. (a): infarct size after IR exposition is expressed as a percentage
of ischemic tissue (% IS/IT). (b): LDH release in the perfusion effluent during the IR was expressed as units per mg of wet tissue weight.
(c)–(e): monitoring of left ventricular pressure (LVP) was used to assess the contractility response to ischemia reperfusion injury. (c) shows
the percentage of contractility recovered at the end of 60min reperfusion. (d) and (e) show the entire time-course of developed LVP (DLVP)
and end diastolic LVP (EDLVP), respectively. Data are means of 6 rats ± SEM. §𝑃 < 0.05 versus IR. §§𝑃 < 0.01 versus IR.
portion of hearts pretreated or not with INF4E and exposed
to IR (Figure 2). Besides, rat hearts were exposed to two
different periods of reperfusion, short and long (20min
and 60min, resp.) to better elucidate the kinetics of the
pharmacological modulation of NLRP3 inflammasome and
related pathways. As shown in Figure 2, the protein level of
NLRP3 was increased in a time-dependent manner, reaching
statistical significance only after the 60min reperfusion.
Notably, the INF4E pretreatment effectively reduced its
upregulation. Western blotting analysis with an antibody
recognizing the C-terminal region of caspase-1 allowed the
identification of two bands corresponding to the procaspase-
1 and the cleaved active p10 subunit of caspase-1. After 20min
of reperfusion the active form of caspase-1 was markedly
increased, without significant changes in the expression of
procaspase-1, although the INF4E-pretreated hearts showed
a slight nonsignificant trend towards reduced procaspase
cleavage. After 60min of reperfusion, both precursor and
active forms of caspase-1 were dramatically increased in
the untreated IR group, whereas the INF4E-pretreatment
significantly prevented procaspase cleavage. As shown in
Figure 2(c), caspase-1 activation is associated with cleavage
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Figure 2: Inflammasome expression and activation in the rat heart exposed to 30min ischemia plus 20 or 60min reperfusion, pretreated or
not with INF4E. Representative Western blotting showing cardiac levels of NLRP3 and of downstream activation of caspase-1, GSDMDC1,
and IL-1𝛽 cleavage assessed on heart extracts. Histograms report densitometric analysis normalized for the corresponding tubulin content.
Data are means of 6 rats ± SEM. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 versus Sham; §§𝑃 < 0.01, §§§𝑃 < 0.001 versus IR.
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Figure 3: IL-1𝛽 concentrations evaluated by ELISA (a) and mRNA levels of IL-1𝛽measured by RT-PCR (b) in extracts of rat hearts exposed
to 30min ischemia plus 20 or 60min reperfusion, pretreated or not with INF4E. Data are means of 6 rats ± SEM. ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001
versus Sham; §§§𝑃 < 0.001 versus IR.
of theGSDMDC1 component of the inflammasome platform,
detectable only after the longest reperfusion time. Interest-
ingly, INF4E pretreatment significantly reduced GSDMCD1
cleavage. Accordingly, the protein levels of the active form of
IL-1𝛽 showed a robust increase after the 60min reperfusion,
as demonstrated by Western blot analysis (Figure 2) and
confirmed by ELISA (Figure 3(a)). The INF4E pretreatment
prevented the slight increase in IL-1𝛽 production due to
20min of reperfusion and strongly reduced the massive
IL-1𝛽 release recorded after 60min of reperfusion (Figures
2 and 3(a)). Interestingly, neither the IR injury nor the
drug treatment affected the mRNA levels of IL-1𝛽 (Fig-
ure 3(b)), thus confirming a selective effect of INF4E on
NLRP3 inflammasome-dependent IL-1𝛽 cleavage rather than
expression.
3.3. INF4E Pretreatment Enhances RISK Pathway Protective
Activity. Very recently, a role for NLRP3 inflammasome
activation in the modulation of the Reperfusion Injury
Salvage Kinase (RISK) pathway has been suggested [20].
Thus, we quantified expression and activity (in terms of
phosphorylation) of the key members of this pathway. After
20min of reperfusion no modulation of the activity and/or
expression level of members of the RISK pathway was
recorded (Figure 4). On the contrary, the longer IR challeng-
ing induced increased phosphorylation rate of both ERK1/2
(Figures 4(a) and 4(b)) and GSK-3𝛽 (Figures 4(a) and 4(d)),
while phosphorylation of Akt tended to increase, without
reaching statistical significance, in untreated hearts exposed
to either short or long IR protocol (Figures 4(a) and 4(c)).
Interestingly, the INF4E pretreatment further increased the
phosphorylation rate of ERK1/2, Akt, and GSK-3𝛽 induced
by the 60min reperfusion in untreated hearts (Figures 4(b)
and 4(c)), suggesting an enhancement of the activation of this
protective pathway by the pharmacological intervention.
3.4. INF4E Pretreatment Improves Mitochondrial Biogenesis
and Energy Metabolism. Since mitochondrial metabolism
is highly involved in the myocytes response to ischemic
insult, and a cross-talk betweenmitochondria andNLRP3has
been described [21], we analyzed markers of mitochondrial
biogenesis after 30min ischemia and 60min reperfusion.
The MtTFA and the NRF-1 were markedly downregulated
by IR. Conversely, mitogenesis was significantly preserved
by INF4E pretreatment (Figures 5(a)–5(c)). A crucial phys-
iological reaction of cardiac myocytes to oxygen deprivation
is the enhancement of mitochondrial energy production, as
suggested in ourmodel by the increased expression of sMtCK
after IR (Figures 5(a) and 5(d)). Intriguingly, the INF4E
pretreatment further stimulated the expression of sMtCK by
25% with respect to untreated rat hearts (Figures 5(a) and
5(d)).
4. Discussion
The present study improves our understanding on the effects
of the NLRP3 inflammasome targeting in acute myocardial
infarction. Here we confirmed that myocardial IR induces
transcription of all the inflammasome components in a time-
dependent way, with slight effect detectable when hearts were
exposed to 20min reperfusion and robust overexpression
and activation at the longest reperfusion time (60min).
These data are in agreement with previous papers showing
increased expression levels of NLRP3 and procaspase-1 in the
infarcted and noninfarcted areas in both cardiomyocytes and
nonmyocyte cell, associated with augmentation of caspase-
1 activity [13, 22]. We also previously demonstrated that an
enhanced susceptibility to a myocardial ischemic insult, due
to metabolic derangements, is paralleled by greater NLRP3
inflammasome activation in the heart [12]. However, the
potential role of the innate immune NLRP3 protein complex
as therapeutic target for cardiac infarction is ill defined.This is
mainly due to the contrasting results so far obtained with tar-
geted deletion of the inflammasome components. Few studies
demonstrated that the depletion of even one of the inflam-
masome complex components, either the sensor (NLRP3)
or the effector enzyme (caspase-1), can prevent its activation
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Figure 4: Prosurvival RISK pathway activation in the rat hearts exposed to 30min ischemia plus 20 or 60min reperfusion, pretreated or
not with INF4E. (a) Representative Western blotting for cardiac levels of total ERK1/2 expression and Thr202/Tyr204 and Thr185/Tyr187
phosphorylation, respectively, total Akt protein expression and Ser473 phosphorylation, and total GSK-3𝛽 protein expression and Ser9
phosphorylation, performed on heart extracts. (b)–(d) Histograms report densitometric analysis of the phosphorylated-to-total form ratio.
Data are means of 6 rats ± SEM. ∗𝑃 < 0.05, ∗∗𝑃 < 0.005, and ∗∗∗𝑃 < 0.001 versus Sham; §𝑃 < 0.05, §§𝑃 < 0.005, and §§§𝑃 < 0.001 versus IR.
and protect the heart preventing ischemic injury and adverse
cardiac remodelling [22–24]. In contrast, Sandanger et al.
[20] showed that absence of NLRP3 results in increased
myocardial infarct size after in vivo IR, whereas Jong et al.
[14] concluded that NLRP3 plays no role in acute myocardial
infarction due to low cardiac expression. As stated by the
same authors, significant differences in the used method-
ologies as well as in the specific endpoint of interest may
help to explain this inconsistency [25]. Besides, a discrepancy
in the outcome between NLRP3−/− and ASC−/− mice after
cardiac IR has been previously observed [13, 26], suggest-
ing the existence of important inflammasome-independent
effects related to targeted genetic deficiency. Thus, only the
evaluation of small molecules able to selectively inhibit the
NLRP3 inflammasome may allow ultimate elucidation of
the potential of NLRP3 inflammasome as pharmacological
target for therapeutic intervention in myocardial IR injury.
Unfortunately, the lack of highly selective pharmacological
inhibitors limits the investigation. INF4E is one of the few
compounds that has been demonstrated to directly target
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Figure 5: Mitochondrial biogenesis and energy metabolism evaluated in the rat hearts exposed to 30min ischemia plus 20 or 60min
reperfusion, pretreated or not with INF4E. (a) Representative Western blotting for cardiac levels of MtTFA, NRF-1, and sMtCK performed
on heart extracts. (b)–(d) Histograms report densitometric analysis normalized for the corresponding tubulin content. Data are means of 6
rats ± SEM. ∗∗∗𝑃 < 0.001 versus Sham; §𝑃 < 0.05, §§𝑃 < 0.005, and §§§𝑃 < 0.001 versus IR.
the NLRP3 inflammasome and inhibit the ATPase activity of
NLRP3 required for its activation. Although there are clear
indications that this drug exerts a specific effect on NLRP3
inflammasome independently of the activating stimulus, the
exact mechanism of action has still to be clarified [16].
Here we demonstrate, for the first time, that administration
of the NLRP3 inflammasome inhibitor INF4E in a single
dose significantly reduces infarct size, the main endpoint to
target in cardioprotective studies.Moreover, the pretreatment
with INF4E preserves systolic function, an index of reduced
myocardial stunning. To the best of our knowledge, so far,
only another small molecule acting as NLRP3 inflammasome
inhibitor has been tested in models of acute myocardial
injury, showing protective effects similar to those recorded
in our ex vivo model of myocardial IR injury [27, 28].
Interestingly, this compound did not reduce infarct size at
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3 h of reperfusion, while it significantly reduced infarct size at
24 h, if administered at the beginning of reperfusion, but not
after 3 h reperfusion [29], thus confirming the importance of
the first period of reperfusion for IR injury development and
the efficacy of pharmacological strategies [5]. Here we docu-
mented significant reduction of infarct size even after 60min
of reperfusion, with INF4E administered as pretreatment. It
has to be noted that our ex vivo model of IR injury may
allow excluding the involvement of infiltrating inflammatory
cells that usually may affect the reperfusion-related injury
as documented in the previous studies investigating the
effects of NLRP3 inhibitors when given during reperfusion
[28, 29]. Thus, our data further extend the previous findings
suggesting that the continuous pharmacological inhibition of
NLRP3 inflammasome pathway already during the ischemic
period may significantly contribute to the beneficial effects
recorded at the end of reperfusion. The kinetics of the
reperfusion injurymay also affect the entity of the drug target
expression and, thus, protection. In fact, when comparing
the 20min reperfusion and the 60min reperfusion models
we observed a progressive expression and activity of NLRP3
inflammasome complex, thus confirming previous findings
on the timing of NLRP3 inflammasome formation in the
heart during ischemia reperfusion [29].
Very recently, a role for NLRP3 inflammasome activa-
tion in the cardioprotective RISK pathway has been faintly
suggested, but not convincingly demonstrated [20]. Here
we measured the entire RISK pathway, which includes
Akt and ERK1/2 activation and GSK3𝛽 inhibition through
phosphorylation [30]. Our data demonstrate that the acti-
vation of ERK/Akt/GSK-3𝛽 signaling is further enhanced
by pharmacological inhibition of the NLRP3 inflammasome
complex and this effect may significantly contribute to its
cardioprotective effects. These data confirm our previous
findings, showing that pharmacological inhibition of NLRP3
inflammasome significantly potentiates the activity of the
prosurvival Akt pathway [31]. Besides, the cross-talk between
NLRP3 inflammasome and RISK pathways is further con-
firmed by the comparative analysis of the expression/activity
of members of both pathways, which show robust increase
only in the 60min reperfusion model in both cases.
Although we demonstrated a direct effect of the tested
compound on NLRP3 inflammasome activation, we cannot
rule out the potential interactions of INF-4E with other sig-
naling pathways, including those involved in the regulation
of the expression of NLRP3 and/or activation of the RISK
pathway. Thus, a further rigorous evaluation of effects of the
tested compound on other signaling pathways affected by IR
is needed to better elucidate its pharmacodynamics profile.
The effects of the pharmacological inhibition of NLRP3
inflammasome on the RISK pathway are closely related
to those recorded on mitochondrial metabolic response.
Indeed, the mitochondrial metabolic dysfunction is crucial
for cardiac damage development, as both the block of mito-
chondrial ATP-sensitive potassium channel (mitoKATP) and
the opening of the mitochondrial permeability transition
pore (mPTP) are common end effectors of the IR injury.
Accordingly, pharmacological strategieswhich aimed to open
the mitoKATP and inhibit mPTP opening effectively reduce
myocardial IR injury and improve cardiomyocytes energy
homeostasis via modulation of the activity of members of
the RISK pathway [32–35].We and others have demonstrated
that the Akt-mediated inactivation of GSK-3𝛽 is critical
for the prevention of myocardial IR injury, being a key
event in the regulation of apoptosis and the enhancement
of mitochondrial biogenesis [36–38]. Besides, the use of
selective GSK-3𝛽 inhibitors evokes protection against IR
injury and promotes cell survival by limiting mPTP opening
[39, 40]. In agreement with the above-mentioned observa-
tions, the INF4E-induced amplification of the RISK pathway
activation here described positively impacted on mitochon-
drial metabolism. In fact, our data clearly demonstrate that
markers of mitochondrial biogenesis, suppressed by IR, were
significantly upregulated by INF4E administration. Besides,
the administered compound enhancedmitochondrial energy
metabolism, shown in terms of reinforced expression of the
sMtCK, which is a marker of increased mitochondrial ATP
production.
Unfortunately, our study does not allow identifying the
specific cell types involved in NLRP3-mediated responses.
Cardiomyocytes are the most prominent cell type in the
heart and loss of contractile tissue is the most important
consequence of a myocardial infarction. However, in car-
diomyocytes, the activation onNLRP3 inflammasome evokes
caspase-1 activation and pyroptosis, but not relevant release
of mature IL-1𝛽 [22, 41]. In contrast, NLRP3 inflammasome
activation inmyocardial fibroblasts induces the production of
large amounts of mature IL-1𝛽, causing a rapid amplification
of the inflammatory response [13, 23, 42]. As cardiomy-
ocytes are crucial target for the IL-1𝛽 produced by resident
fibroblasts, which impairs contractile function and induces
apoptotic cell death, we may speculate that the beneficial
effects of INF4E are due, at least in part, to an indirect
improvement in cardiomyocytes functionality.
5. Conclusion
Taken together, our results strengthen the crucial role of
NLRP3 inflammasome activation even in the early step of
myocardial injury caused by IR and show, for the first time,
that its pharmacological inhibition by INF4E reduced the
organ injury/dysfunction. Preservation of cardiac function by
INF4E is, at least in part, attributable to a cardioprotective
effect mediated by the activation of the RISK survival path-
ways and the improvement inmitochondrial function, which,
in turn, may improve cardiac function and postischemic
outcome. It has to be stressed, however, that the lack of
long-term evaluation as well as data on drug effects when
administered during reperfusion limit the interpretation of
the clinical transferability of our findings. Thus, further rig-
orous evaluations are needed to gain a better understanding
of both efficacy and the mechanism of action of INF4E in the
settings of acute myocardial infarction.
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